Weight-loss drug Ozempic launched in India, priced at Rs 8,800 a month

HealthIANS
Advertisement
New Delhi, Dec 12 : Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.

Ozempic -- a once-weekly injectable formulation of semaglutide -- is approved in India for adults with uncontrolled type 2 diabetes, along with diet and exercise.

The drug is available in three dosage forms -- 0.25mg, 0.5 mg, and 1mg -- in a single-use pre-filled pen called Novofine Needles designed for painless subcutaneous injection, the drug maker said.

The 0.25 mg, which is the initial dose, is priced at Rs 8,800, followed by Rs 10,170 for 0.5 mg and Rs 11,175 for 1 mg. Each pen contains four weekly doses.

“Bringing Ozempic to India is a major milestone. Backed by global trust, proven clinical excellence, and world-class quality, reinforced by a robust supply chain, Ozempic offers Indian doctors an effective treatment choice,” said Vikrant Shrotriya, Managing Director, Novo Nordisk India.

“Our goal is to provide patients with an innovative and accessible therapy that offers improved glycaemic control, meaningful weight management, and long-term heart and kidney protection -- all delivered through a simple, easy-to-use pen device. This once-weekly treatment demonstrates Novo Nordisk’s ongoing commitment to better health outcomes and chronic disease care,” Shrotriya added.

Ozempic was approved by the US Food and Drug Administration (FDA) in 2017 for type 2 diabetes. Since then, it has been widely used off-label for weight loss due to its appetite-suppressing effects. It also protects patients from the risk of cardiovascular events and kidney issues, Novo said.

The company noted that Ozempic is a GLP-1 receptor agonist that helps improve glycaemic control and reduce HbA1c (a measure of glucose control); regulate appetite and food intake by acting on areas of the brain that control hunger; support weight loss in people with type-2 diabetes; and reduce risks of cardiovascular and kidney complications associated with diabetes.

Advertisement

Note: The content of this article is sourced from a news agency and has not been edited by the ap7am team.

OzempicNovo Nordiskweight-loss drugsemaglutidetype 2 diabetesIndiaFDA approvedVikrant ShrotriyaNovofine Needles

More News

IPL 2027: All ten teams' retained players list, slots available details ahead of mini-auction

17 Nov, 21:29

Dhoni's presence as mentor will help next generation of CSK players: Rashid Latif

17 Nov, 21:27

IPL 2027: Starc, Head, Pathirana among big names out as all franchises release players

17 Nov, 21:25

'Dhoni was mentoring players even as captain, so it's nothing new for him,' says Irfan Pathan

17 Nov, 21:23

'Mai har ek pal ka shayar hu': MS Dhoni shares heartfelt video as 'fans proved me wrong'

17 Nov, 21:21

Andhra Pradesh CM Chandrababu urges Centre to provide funds for cyclone relief

17 Nov, 21:20

Telangana’s 4,000 MW Yadadri plant to achieve full capacity soon

17 Nov, 19:01

Reports of unwanted Instagram recommendations in India halved over past year: Meta

17 Nov, 19:00

Trump watches as PM Modi picks up Indian flag marker from floor, video goes viral

17 Nov, 18:58

Rajinikanth's daughter Soundarya shares pictures of their family getaway in Greece; says 'What amazing memories we’ve made in Athens!'

17 Nov, 18:56

When Jackie Shroff gave 10x returns to Archana Puran Singh on pending principal amount from struggling days

17 Nov, 18:54

'There was no one like Dhoni, and can't see anyone in next 10 years either': Coach MP Singh

17 Nov, 18:53

Dulquer Salmaan's 'Aakasamlo Oka Tara' cleared for release with U/A certificate

17 Nov, 18:52

Gas leak from ONGC well in Andhra brought under control

17 Nov, 18:50

‘Learned the meaning of simplicity…’: Ruturaj Gaikwad’s heartfelt tribute to Dhoni

17 Nov, 18:49

Dhanush, Mammootty-starrer 'Om' cleared for release with U/A certificate!

17 Nov, 18:47

Sri Lanka lose 15 WTC points, Pakistan docked five for slow over-rate during Rawalpindi Test

17 Nov, 18:46

'IPL will not be the same': Cricket fraternity pays emotional tribute to MS Dhoni after retirement

17 Nov, 18:44

Rahul Gandhi responds to backlash over 'lap' remark, shares temple sculpture

17 Nov, 18:43

PM Modi is 'a very tough man': Trump after meeting Quad counterparts

17 Nov, 17:06
..More News